key: cord-0692889-pfymz752
authors: Pérez-García, Felipe; Bailén, Rebeca; Torres-Macho, Juan; Fernández-Rodríguez, Amanda; Jiménez-Sousa, Maria Ángeles; Jiménez, Eva; Pérez-Butragueño, Mario; Cuadros-González, Juan; Cadiñanos, Julen; García-García, Irene; Jiménez-González, María; Ryan, Pablo; Resino, Salvador
title: Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019
date: 2021-09-08
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2021.736028
sha: 4adf727c2685813bd9f9aa92f537c6b53ccc5fda
doc_id: 692889
cord_uid: pfymz752

Background: Endothelial Activation and Stress Index (EASIX) predict death in patients undergoing allogeneic hematopoietic stem cell transplantation who develop endothelial complications. Because coronavirus disease 2019 (COVID-19) patients also have coagulopathy and endotheliitis, we aimed to assess whether EASIX predicts death within 28 days in hospitalized COVID-19 patients. Methods: We performed a retrospective study on COVID-19 patients from two different cohorts [derivation (n = 1,200 patients) and validation (n = 1,830 patients)]. The endpoint was death within 28 days. The main factors were EASIX [(lactate dehydrogenase (*) creatinine)/thrombocytes] and aEASIX-COVID (EASIX (*) age), which were log(2)-transformed for analysis. Results: Log(2)-EASIX and log(2)-aEASIX-COVID were independently associated with an increased risk of death in both cohorts (p < 0.001). Log(2)-aEASIX-COVID showed a good predictive performance for 28-day mortality both in the derivation cohort (area under the receiver-operating characteristic = 0.827) and in the validation cohort (area under the receiver-operating characteristic = 0.820), with better predictive performance than log(2)-EASIX (p < 0.001). For log(2) aEASIX-COVID, patients with low/moderate risk (<6) had a 28-day mortality probability of 5.3% [95% confidence interval (95% CI) = 4–6.5%], high (6–7) of 17.2% (95% CI = 14.7–19.6%), and very high (>7) of 47.6% (95% CI = 44.2–50.9%). The cutoff of log(2) aEASIX-COVID = 6 showed a positive predictive value of 31.7% and negative predictive value of 94.7%, and log(2) aEASIX-COVID = 7 showed a positive predictive value of 47.6% and negative predictive value of 89.8%. Conclusion: Both EASIX and aEASIX-COVID were associated with death within 28 days in hospitalized COVID-19 patients. However, aEASIX-COVID had significantly better predictive performance than EASIX, particularly for discarding death. Thus, aEASIX-COVID could be a reliable predictor of death that could help to manage COVID-19 patients.

Around 80% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients develop mild-to-moderate illness, 15% severe illness, and 5% critical illness, including acute respiratory distress syndrome, septic shock, and multiorgan failure (1) . Severe coronavirus disease 2019 is related to high mortality, mostly in older people with comorbidities such as diabetes and cardiovascular diseases (2) . Besides, the excessive hospital demand generated by the COVID-19 pandemic during the first wave caused a high request for intensive care beds in Madrid, Spain (3), affecting the quality of medical care and impacting mortality due to .

A deregulated pro-inflammatory response (cytokine storm) usually appears in patients with severe COVID-19, which leads to coagulopathy and endothelial damage with frequent episodes of thromboembolism (1, 5) . Widespread endotheliitis with diffuse microcirculatory injury in the lung and other organs (brain, heart, kidneys, gut, and liver) is a central feature of severe . This disturbed coagulation is strongly associated with acute respiratory distress syndrome, multiorgan failure, and mortality, which is higher than in patients with COVID-19-unrelated pneumonia (1) .

During the COVID-19 pandemic, many biomarkers to predict mortality have been reported (6, 7) , including lactate dehydrogenase, creatinine, and thrombocyte count. These three markers are part of the Endothelial Activation and Stress Index (EASIX), a powerful score that was initially developed to predict survival in patients with acute graft vs. host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (8) . Endothelial activation is the common trigger of several complications occurring after allo-HSCT, including transplant-associated microangiopathy, sinusoidal obstruction syndrome, and GVHD (9) . In the last years, EASIX has also been validated as a predictor for the development of other allo-HSCT complications, including non-relapse mortality (10, 11) , fluid overload (12) , and sinusoidal obstruction syndrome (13) . This score has also been validated in other hematological malignancies outside of the HSCT setting (14, 15) .

Because coagulopathy and endothelial dysfunction are critical in the evolution of patients with COVID-19, we aimed to assess whether the EASIX score can predict 28-day mortality in hospitalized COVID-19 patients.

We performed a retrospective study on consecutively hospitalized patients between March 1 and May 31, 2020 (during the first wave of the COVID-19 pandemic) with a laboratory-confirmed with a laboratory-confirmed SARS-CoV-2 infection by real-time polymerase chain reaction. Our study population consisted of two cohorts from two hospitals in Madrid, Spain, which were previously described:

(i) Derivation cohort from Infanta Leonor University Hospital (ILUH) (16, 17) . Initially, 1,968 patients were included. However, we discarded 391 patients due to missing values for the EASIX variables and 377 patients due to transfer to another institution within 28 days after hospital admission, resulting in a final study population of 1,200 patients. The Ethics Committee of ILUH (Code ILUH R 027-20) approved the study.

(ii) Validation cohort from La Paz University Hospital (LPUH) (18) . Initially, 2,226 patients were included. We discarded 396 patients due to missing values for the EASIX variables, resulting in a final study population of 1,830 patients. The Ethics Committee of LPUH (Code PI-4072) approved the study.

The study was conducted according to the Declaration of Helsinki. Written informed consent waiver was obtained from the Ethics Committees due to the retrospective nature of the study. In addition, the database was anonymized for statistical analysis. The research followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement (19) .

Demographic and clinical data were extracted from medical records and managed using Research Electronic Data Capture (REDCap). We included age, sex, smoking habit, comorbidities [chronic heart disease, hypertension, chronic pulmonary disease, asthma, chronic kidney disease, liver disease (cirrhosis), neoplasm, hematological malignancy, obesity, diabetes, and dyslipidemia], laboratory findings, and signs at hospital admission [oxygen saturation, hematocrit, blood counts (lymphocytes, neutrophils, thrombocytes), aspartate aminotransferase and alanine aminotransferase, lactate dehydrogenase, glucose, creatinine, sodium, potassium, and C-reactive protein].

EASIX was calculated according to the previously reported formula [lactate dehydrogenase (IU/L) * creatinine (mg/dl)/thrombocyte count (10 9 cells/L)] (8) . Additionally, we calculated the aEASIX-COVID (age-adjusted EASIX for COVID-19), which incorporates age at COVID-19 diagnosis to the previous formula [EASIX * age (years)]. Age was added to EASIX because it is a significant predictor of mortality in and is also an easy variable to obtain at the time of the patient's diagnosis. Both indexes were log 2 transformed.

The primary endpoint was 28-day all-cause mortality. The baseline was the date at hospital admission. At the follow-up censoring date (May 31, 2020), the clinical status of the patients was discharged alive, currently hospitalized alive, or dead. When a patient was readmitted during the study period, a single hospital admission episode was considered for the purposes of the analysis.

Quantitative variables were expressed as the median and interquartile range, and categorical variables were shown as absolute count (percentage). Comparisons between groups were performed using the Mann-Whitney U test for continuous variables and the chi-squared or two-tailed Fisher's exact test for categorical variables.

We assessed the risk of death using the survival analysis (Kaplan-Meier and Cox regression analyses). The Kaplan-Meier product-limit method was used to estimate survival probabilities at 28 days, and the log-rank test was used to calculate the differences between groups and trends. Cox proportionalhazards models were used to study the association between risk factors (age, sex, smoking habit, comorbidities, laboratory findings, and signs at hospital admission) and mortality during the first 28 days. Continuous variables (including EASIX and aEASIX-COVID) were log 2 -transformed (base-2 logarithms). First, we performed univariate Cox regression analyses. Then, we performed multivariate Cox regression analyses with variables that had a p-value ≤ 0.05, missing values ≤10%, and low collinearity between them (r < 0.5), which were further selected by a stepwise forward selection method (pin < 0.05 and pout < 0.10).

Internal validation of the predictive model was made using 20fold cross-validation. The predictive performance of death within 28 days of hospital admission for EASIX and aEASIX-COVID was evaluated by examining calibration (Hosmer-Lemeshow test) and discrimination [area under the receiver-operating characteristic (AUROC)] measures. We calculated the prediction error for EASIX and aEASIX-COVID in both cohorts using the Brier score. Differences between AUROC models were assessed using the Delong test. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for the different deciles of the distribution.

Statistical analysis was performed using Stata/IC 15.1 (StataCorp, Texas, USA) and GraphPad Prism 7.04 (GraphPad Software, Inc., California, USA). Table 1 shows baseline characteristics of COVID-19 patients, stratified by survival/death within 28 days of hospital admission at ILUH (derivation cohort) and LPUH (validation cohort). In both cohorts, patients who died were significantly older, more frequently male, and presented more comorbidities such as chronic heart disease, hypertension, chronic kidney disease, solid neoplasm, hematological malignancy, diabetes, and dyslipidemia. Besides, patients who died showed significantly lower values of hematocrit, lymphocytes, thrombocytes, and alanine aminotransferase, whereas they had higher values of neutrophils, aspartate aminotransferase, lactate dehydrogenase, glucose, creatinine, potassium, and C-reactive protein. Mortality rate within 28 days was significantly lower in ILUH (derivation cohort, 17.7%) than in LPUH (validation cohort, 22.5%) (p = 0.001).

Log 2 EASIX was associated with a higher risk for death within 28 days in the derivation cohort [adjusted hazard ratio (aHR) = 1.55; p < 0.001] and the validation cohort (aHR = 1.41; p < 0.001) (Supplementary Table 1 ). Furthermore, log 2 aEASIX-COVID showed slightly higher mortality risk values for 28-day death compared with log 2 EASIX (Supplementary Table 2) , both in the derivation (aHR = 1.61; p < 0.001) and in the validation cohort (aHR = 1.51; p < 0.001).

Log 2 EASIX presented suitable values of calibration (chi-squared = 11.04; p = 0.198; Figure 1A) , discrimination (AUROC = 0.784; Figure 1B) , and an acceptable prediction error (Brier score = 0.119) at the derivation cohort. At the validation cohort, log 2 EASIX showed similar predictive performance values to the derivation cohort for calibration (chi-squared = 7.36; p = 0.498; Figure 1C ), discrimination (AUROC = 0.774; Figure 1D ), and an admissible prediction error (Brier score = 0.141). Log 2 EASIX PPV increased with deciles but did not exceed 61% in the derivation cohort and 70% in the validation cohort, and NPV decreased with the increase of the deciles but was not <80% in both cohorts (Supplementary Table 3) .

Log 2 aEASIX-COVID showed better values of predictive performance than log 2 EASIX for calibration and discrimination in the derivation cohort [chi-squared = 3.09 (p = 0.928; Figure 1A ) and AUROC = 0.827 (p < 0.001; Figure 1B) , respectively] and in the validation cohort [chi-squared = 6.66 (p = 0.574; Figure 1C ) and AUROC = 0.820 (p < 0.001; Figure 1D) , respectively]. Moreover, Brier scores of log 2 aEASIX-COVID were slightly lower than those obtained for log 2 EASIX (0.111 for derivation and 0.131 for validation cohorts). Internal validation showed an AUC of 0.832 (95% CI = 0.786-0.849) in the derivation cohort and 0.818 (95% CI = 0.795-0.842) in the validation cohort. Log 2 aEASIX-COVID PPV raised with the increase in deciles but did not exceed 67% in the derivation cohort and 72% in the validation cohort. Besides, NPV decreased with increasing deciles but was not below 80% in both cohorts (Supplementary Table 4 ).

We considered the risk of 28-day mortality, joining the two cohorts, in three strata (low/moderate, high, and very high). For log 2 EASIX, 28-day mortality probability values were 7.8% for patients with low/moderate risk (<0), 18.6% for high risk (0-1), and 45.4% for very high risk (>1) (Figure 2A) . The cutoff of log 2 EASIX = 0 showed a PPV of 29.8% and NPV of 92.2%, and log 2 EASIX = 1 showed a PPV of 45.3% and NPV of 87.4% ( Table 2) . For log 2 aEASIX-COVID, 28-day mortality probability values were 5.3% for patients with low/moderate risk (<6), 17.2% for high risk (6, 7) , and 47.6% for very high risk (>7) (Figure 2B) . The cutoff of log 2 aEASIX-COVID = 6 showed a PPV of 31.7% and NPV of 94.7%, and log 2 aEASIX-COVID = 7 showed a PPV of 47.6% and NPV of 89.8% ( Table 2 ). The Kaplan-Meier curve for the 28-day mortality also showed a different evolution of patients according to the different risk strata according to log 2 EASIX ( Figure 2C ) and log 2 aEASIX-COVID ( Figure 2D ).

We evaluated EASIX for predicting mortality within 28 days in hospitalized COVID-19 patients from two large datasets in Spain.

The main findings of our study were as follows: (i) the increase in EASIX values, especially in aEASIX-COVID, was linked to higher 28-day mortality. (ii) EASIX and aEASIX-COVID had a good predictive performance, but only aEASIX-COVID had AUROC >0.8 in the derivation and validation cohorts. (iii) EASIX and aEASIX-COVID were more reliable in predicting patient survival than death because the NPV values were much higher than the PPV values. (iv) EASIX and aEASIX-COVID allowed the stratification of COVID-19 patients into three risk categories of 28-day mortality. Many predictive scores for mortality in COVID-19 patients have been developed (20, 21) . However, most of these predictive scores do not exceed the AUROC of 0.8, including comorbidities related to poor COVID-19 prognosis or variables that are not always available in clinical practice. Besides, these scores require laborious calculations as long as they are based on complex multivariate models. Therefore, we hypothesized that EASIX, a simple score developed for endotheliopathy associated with allo-HSCT, could also predict mortality in COVID-19 patients because endotheliopathy is crucial for its pathophysiology (1) . EASIX was initially developed by Luft et al. as a predictor of survival in patients with acute GVHD after allo-HSCT (8) and later validated to predict mortality related to different post-HSCT complications (10) (11) (12) (13) (14) (15) . For the development of EASIX, the authors chose three laboratory parameters that were part of the classical diagnostic criteria of thrombotic microangiopathy (creatinine, lactate dehydrogenase, and thrombocyte counts) due to both their simplicity and their association with endothelial dysfunction and microangiopathy (8) . Widespread endotheliitis and coagulopathy are also keys in the pathophysiology of COVID-19 (1) . Recently, Luft et al. (22) have reported in two cohorts of 100 and 126 patients that EASIX predicts COVID19 outcome and may discriminate patients who need intensive surveillance. Besides, high EASIX values correlated with increased serum values of endothelial (angiopoietin-2, CXCL8, soluble thrombomodulin, and suppressor of tumorigenicity-2) and inflammatory (CXCL9, IL18, and IL18BPa) biomarkers (22) . In our study, EASIX showed reasonable accuracy in predicting death within 28 days in hospitalized COVID-19 patients despite its simplicity and the fact that it was developed in a different setting. Both the simplicity and applicability make this score especially useful in healthcare overload and low-resource settings.

Moreover, because age has largely been described as one of the most important predictors of mortality in patients with , we postulated that an age-adjusted EASIX (aEASIX-COVID) might increase its predictive performance for 28-day mortality. In our study, the predictive performance FIGURE 1 | Predictive performance of death within 28 days in COVID-19 patients. Calibration plots (A,C) were performed from Hosmer-Lemeshow test. Discrimination analysis was performed by AUROC curves (B,D), and p-values were calculated using Delong test. Abbreviations: X 2 , Chi-squared; AUROC, area under the receiver-operating characteristic curve; 95% CI: 95% confidence interval; EASIX, endothelial activation and stress index; aEASIX-COVID: age-adjusted EASIX at COVID-19 diagnosis.

of the aEASIX-COVID was significantly superior to the EASIX (initial model) in our two cohorts (derivation and validation) (23) . However, EASIX and aEASIX-COVID were more reliable in predicting patient survival than death because NPV values were much higher than PPV values. Furthermore, the predictive performance of aEASIX-COVID for 28-day mortality was similar to Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) (24) and PANDEMYC scores (17) , which were both constructed from patients included in our study. However, SEIMC and PANDEMYC scores are more complex to calculate because they are constructed with a higher number of variables (seven to nine variables) than aEASIX-COVID (four variables), and their developments were based on more complex calculations.

Our study presents some limitations. First, this retrospective study only included patients belonging to the first pandemic wave, which was associated with higher mortality rates worldwide. Another limitation could be that aEASIX-COVID relied exclusively on hospitalized patients. Consequently, its applicability in primary care settings, where routine laboratory tests are not usually used, is unknown. Finally, a limitation common to all reported COVID-19 prognostic models is that our study was carried out in Spain, limiting our findings' extrapolation to other countries and healthcare settings. In this regard, the level of hospital saturation generated in the first wave of the COVID-19 epidemic could affect our results (new admissions, number of transfers to other hospitals daily, patient/physician ratio, available intensive care unit beds, among others). Consequently, additional studies are needed to validate FIGURE 2 | Prediction of 28-day mortality in hospitalized COVID-19 patients according to log 2− aEASIX and log 2− aEASIX-COVID stratified into six risk categories. (A,B) probability of death within 28 days of hospitalization according to log 2− aEASIX and log 2− aEASIX-COVID, respectively. Values are expressed as frequency and 95% confidence interval (95% CI). (C,D) Survival curves (Kaplan-Meier curve) by log 2− aEASIX and log 2− aEASIX-COVID risk categories, respectively. P-value was calculated by log-rank trend tests. Abbreviations: Fr, frequency; 95% CI, 95% confidence interval; EASIX, endothelial activation and stress index; aEASIX-COVID, age-adjusted EASIX at COVID-19 diagnosis. This study also has several strengths. First, our research has a large sample size and a large number of events, both in the derivation and validation cohorts. Besides, our research adheres to the TRIPOD recommendations. Finally, the aEASIX-COVID score is easy to calculate with normally accessible variables, which would allow rapid decision-making in COVID-19 patients.

Both EASIX and aEASIX-COVID were associated with death within 28 days in hospitalized COVID-19 patients. However, aEASIX-COVID had significantly better predictive performance than EASIX, particularly for discarding death. Thus, our findings suggest that aEASIX-COVID could be a reliable predictor of death that could help to manage COVID-19 patients.

The datasets used and/or analyzed during the current study may be available from the corresponding author upon reasonable request.

The studies involving human participants were reviewed and approved by Infanta Leonor University Hospital Ethics Committee (Code: ILUH R 027-20) and the Ethics Committee of La Paz University Hospital (Code: PI-4072). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. 

We would like to thank all the frontline ILUH and LPUH staff for their dedication and their work in facing this pandemic under enormous pressure.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2021.736028/full#supplementary-material COLLABORATORS

A) Derivation cohort from Infanta Leonor University Hospital (ILUH)

Andrea Lazaro; Adriana Campoverde

Mariano Matarranz; Berta Montero; Elsa Izquierdo; Helena Notario; Beatriz Sanchez

Isamel Escobar; Carlos Bibiano; Paz Arranz

B) Validation cohort from La Paz University Hospital (LPUH): José Ramón Arribas

Jesús Frías

Rocío Nuñez Cabetas

Silvia Ossaba Vélez; Inmaculada Pinilla; Emilio Cuesta

Renzo Tejada Sorados

Martín Pilares Barco

Miguel Silvestre Niño; Frank Perdomo García

Isabel Arenas Berenguer

María Ángeles Molina; Nataly Cancelliere Fernández; Sivia Pastor Yvorra

María Angeles Martinez-López; Victor Hontañon

Ivo Vives Beltrán

Yeray Untoria Tabares; Carlos Lahoz

Sarai Quirós Fernández; Delia Romera Cano

Victoria Arnalich Montiel; Pablo Mariscal Aguilar

Andony García; Cristina Arévalo; Carola Gutiérrez

Belén Estébanez; Eva Flores; Mónica Hernández

Elena Alvar; Lucía Serrá; Fabricio Iannuccelli

Esteban García de las Heras

Sergio Zurita; Mercedes López-Martinez; Teresa Prim; Julía Alvárez Del Vayo; Gabriela Alcaraz; Luis Castro

Leyre Díez Porres; María Varela Cerdeira

Silvia Arribas Terradillos

Lucia Brieba Plata; Fernando Cadenas Gota; Paloma Carrera Vázquez

Inés Ferrer Ortiz; Lydia de la Fuente Regaño

Nelsa González Aguado; Sofía González García; Jorge Guisández Martín; Paula Alejandra Hernández Liebo

Marta Virgós Varela; Marta Yagüe Barrado; Natalia Yustas Benitez.; M a Concepción Núñez

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

Coronavirus disease 2019 (COVID-19): a clinical update

Flexibility and bed margins of the community of madrid's hospitals during the first wave of the SARS-CoV-2 Pandemic

A closer look into global hospital beds capacity and resource shortages during the COVID-19 pandemic

COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction

Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review

Early prediction keys for COVID-19 cases progression: a meta-analysis

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis

Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions

EASIX and mortality after allogeneic stem cell transplantation

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation

Endothelial activation and stress index (EASIX) at admission predicts fluid overload in recipients of allogeneic stem cell transplantation

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

EASIX for prediction of survival in lower-risk myelodysplastic syndromes

Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study

The PANDEMYC score. An easily applicable and interpretable model for predicting mortality associated with COVID-19

A cohort of patients with COVID-19 in a major teaching hospital in Europe

Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement

Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study

Prediction models for severe manifestations and mortality due to COVID-19: a rapid systematic review. medRxiv

EASIX for prediction of outcome in hospitalized SARS-CoV-2 infected patients

Prognosis and prognostic research: validating a prognostic model

Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score

PR reports grants and personal fees from GILEAD and MSD and personal fees from AbbVie and ViiV Healthcare, outside the submitted work. SR reports reports grants from GILEAD and MSD, outside the submitted work.The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.